Inversago Pharma, based in Montreal, Canada, is working on safer generations of peripherally-acting cannabinoid receptor-1 (CB1) inverse agonists, based on research carried out by George Kunos ...

Even at the lowest doses tested, the incidences of adverse effects were increased, albeit not significantly, which according to Aronne could indicate that “the CB1 mechanism lacks a viable ...

CB1 receptors serve as switches that can turn various biological processes on or off. Under normal circumstances, the CB1 receptors are activated by cannabis-like substances that are produced in ...

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.